PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy

A Phase I open-label, multicenter study, to evaluate the safety, feasibility, and maximum tolerated dose (MTD) of treating children with newly diagnosed DIPG or recurrent neuroblastoma with molecular targeted therapy in combination with adoptive cell therapy (Total tumor mRNA-pulsed autologous Dendritic Cells (DCs) (TTRNA-DCs), Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT) and Autologous G-CSF mobilized Hematopoietic Stem Cells (HSCs)).

Trial Details

NCT ID
NCT04837547
Phase
PHASE1
Sponsor
University of Florida
Status
RECRUITING
Cancer Type
Brain Cancer
Interventions
  • Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT)
Locations (sample)
  • Gainesville, Florida, United States|29.65163,-82.32483
  • Charlotte, North Carolina, United States|35.22709,-80.84313
  • Hershey, Pennsylvania, United States|40.28592,-76.65025

Key Eligibility Criteria

  • Subjects must have proven pediatric cancer with confirmation at diagnosis or at the time of recurrence/progression and clinical determination of di…
  • Disease Status:
  • High Risk Neuroblastoma-
  • Patients that have relapsed following standard of care therapy or having progressed during standard of care therapy and non-responsive/progressive …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →